A r t i c l e s
Interleukin 17 (IL-17)-producing helper T cells (T H 17 cells) and CD4 + induced regulatory T cells (iT reg cells) emerge from a shared developmental axis 1 . While transforming growth factor-β (TGF-β) contributes to the developmental programming of both subsets, the proinflammatory cytokine IL-6 favors T H 17 cell development at the expense of iT reg cell development [2] [3] [4] [5] [6] . Conversely, retinoic acid (RA), a metabolite of vitamin A produced by intestinal stromal cells and dendritic cells (DCs) that express retinaldehyde dehydrogenases 7 , acts in concert with TGF-β to promote expression of the transcription factor Foxp3 and T reg cell development while potently inhibiting T H 17 cell development [8] [9] [10] [11] [12] . A substantial percentage of T H 17 cells resident in the intestinal lamina propria have expressed Foxp3 at some point during their development, which indicates a dynamic relationship between RORγt + T H 17 cells and Foxp3 + T reg cells developing in the intestines 5 . Whereas IL-6 signaling induces phosphorylation of the transcription factor STAT3 that is required for expression of the transcription factor RORγt and T H 17 cell development, the actions of RA are at least partially dependent on IL-2, which induces phosphorylation of STAT5 that is required for Foxp3 expression and iT reg cell development, and which suppresses T H 17 cell development 9, 13, 14 . Many DNA-binding sites targeted by STAT3 in gene loci associated with the T H 17 lineage can also bind STAT5, which provides a mechanism for competitive antagonism of these trans-acting factors downstream of signaling via the IL-6 and IL-2 receptors 15 .
While IL-6 is important for reciprocally promoting T H 17 cell development and repressing iT reg cell development, its effects in countering RA-mediated inhibition of T H 17 cell development are incomplete 9, 14 . Thus, even at saturating doses of IL-6, T H 17 cell development is suppressed by RA, which suggests that additional signals might be needed to override the dominant RA signaling in the gut. IL-1 is another proinflammatory cytokine that promotes T H 17 cell development while subverting T reg cell development 2, 16 , and it has been shown to be important in the development of T H 17 cells in the gut, at least at steady state 17 . However, other reports have suggested that signaling via IL-1β and its receptor IL-1R is dispensable in the differentiation of intestinal T H 17 cells at steady state, on the basis of studies of mice deficient in the adaptor MyD88, which have impaired signaling via IL-1R and Toll-like receptors 18, 19 . The role of IL-1 signaling during pathogen-induced intestinal inflammation has not been well studied. Therefore, both the mechanism by which IL-1 promotes intestinal T H 17 cell development and the role of IL-1 in T H 17 cell development during acute intestinal inflammation, particularly in disease models in which T H 17 cells are protective, remain largely undefined 20, 21 .
In this study, we sought to define the role of IL-1 in regulating the developmental balance of T H 17 cells and iT reg cells, with emphasis on its effects on the intestine during challenge with the enteropathogenic bacterium Citrobacter rodentium, which elicits a T H 17 pathway response that is required for host protection 3, 21, 22 . Our results indicated that IL-1 signaling was needed to enhance IL-6 signaling A r t i c l e s to fully override RA-mediated Foxp3 expression and induce protective T H 17 cell responses. Through a mechanism dependent on the transcription factor NF-κB, IL-1 signaling repressed the expression of SOCS3, a feedback inhibitor of tyrosine phosphorylation of STAT3 induced by Jak kinase. Inhibition of SOCS3 expression by IL-1 signaling resulted in an increased amplitude and duration of the tyrosine-phosphorylation of STAT3 downstream of signaling by T H 17-polarizing cytokines without altering the IL-2-induced tyrosine-phosphorylation of STAT5. IL-1 signaling therefore altered the balance of the binding of STAT3 versus that of STAT5 to shared consensus sequences in developing T cells, including the conserved noncoding sequence 2 (CNS2) element in the Foxp3 locus that regulates stability of Foxp3 expression, as well as target sequences in the Il17a-Il17f locus. Thus, IL-1 signaling modulated STAT activation downstream of cytokine receptors differently to control the T H 17 cell-iT reg cell developmental fate. RESULTS IL-1b reverses RA-induced inhibition of T H 17 differentiation IL-6 counteracts the effects of the RA-mediated suppression of T H 17 cell development, albeit incompletely 9 . In the course of investigating the role of IL-1β in promoting T H 17 cell development, we found that in contrast to IL-6, IL-1β completely reversed the impairment of T H 17 differentiation observed when DCs from mesenteric lymph nodes (MLNs) were used to activate naive CD4 + T cells (Fig. 1a,b) . Moreover, IL-1β was comparable to the retinoic acid receptor (RAR) inhibitor LE450 in blocking the effects of RA (Fig. 1a,b) . Accordingly, the addition of IL-1β overrode the inhibition of T H 17 differentiation by RA, regardless of RA concentration (Fig. 1c,d ). This result was not due to downregulation of the receptor subunits RAR or RXR, as all members of this family were either unchanged or modestly increased by IL-1 signaling, and this occurred despite partial RA-mediated down-modulation of IL-1R1, which had higher expression by developing T H 17 cells than by T H 0 cells (Supplementary Fig. 1) .
To extend the studies reported above, we investigated the effects of IL-1 on reversing the expression of Foxp3 supported by RA signaling in developing T H 17 cells (Fig. 1e,f) 21 ; data not shown) resulted in impaired clearance of bacteria and heightened injury of the intestinal mucosa (Fig. 2a,b and Supplementary Fig. 2a,b) . Infection of mice deficient in IL-1R1 (Il1r1 −/− mice) showed similarly impaired host protection with a concomitant decrease in colonic production of IL-17A but not of interferon-γ (IFN-γ) (Fig. 2c,d) . Those results were similar to published findings obtained with mice deficient in the IL-17 receptor component IL-17RA and were consistent with the possibility of a role for IL-1 in promoting T H 17 pathway-dependent host protection 21 . Depletion of IL-17-producing cells from Il1r1 −/− Il17f Thy-1.1 mice did not significantly alter this result (Fig. 2a,b) , which suggested that a major effect of IL-1R1 deficiency during this period of the infection was mediated by its actions on these cells. Production of IL-22 in the infected colon was reduced in IL-1R1-deficient mice, but only at the peak time point (day 7 after infection; Supplementary Fig. 2c ).
We observed a transient increase in Foxp3 + CD4 + T cells in the large intestine and draining lymph nodes of IL-1R1-sufficient mice during infection (days 3-5; Supplementary Fig. 3a,b) , as well as a shift in the balance of IL-17 + cells versus Foxp3 + cells recovered from the large intestine of infected IL-1R1-deficient mice ( Supplementary  Fig. 3c,d) . Therefore, we posited that infection-induced IL-1 signaling in CD4 + T cells might be needed to overcome the T reg cell Fig. 3e ). We then determined whether the impaired T H 17 cell development in the IL-1R1-deficient mice was due to a failure to overcome RA-mediated repression. We treated C. rodentium-infected IL-1R1-deficient Il17f Thy-1.1 Foxp3 GFP mice with an antagonist of RAR or vehicle following inoculation with C. rodentium ( Fig. 3c,d ). Blockade of RAR signaling in infected IL-1R1-deficient mice significantly reversed the deficit in IL-17-producing T cells in both the lamina propria of the large intestine and MLNs but not in the spleen; this blockade in the IL-1R1-deficient mice resulted in decreased bacterial loads associated 
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A r t i c l e s with protection from mucosal injury and less weight loss, but such blockade in their IL-1R1-sufficient counterparts did not (Fig. 3e,f and Supplementary Fig. 4 ). Collectively, these findings identified a role for pathogen-induced IL-1 signaling in overriding the iT reg cell programming favored by RA-producing intestinal DCs to induce protective T H 17 cell responses to microbial antigens.
IL-1b counters RA-driven repression of T H 17 cells RA suppresses T H 17 cell development in favor of iT reg cell development at least in part via an IL-2-dependent mechanism 9, 14 . To determine whether IL-1 signaling might also modulate IL-2-dependent suppression of T H 17 differentiation, we assessed the effect of adding increasing concentrations of IL-2 to cultures of naive CD4 + T cells activated by antigen under T H 17-polarizing conditions, with or without the addition of IL-1β. In the absence of added IL-1β, increasing concentrations of IL-2 suppressed the frequency of IL-17 + cells, with a reciprocal increase in the frequency of Foxp3 + cells (Fig. 4a,b) , as reported 14 . IL-1β abrogated the suppressive effects of IL-2, regardless of the concentration of IL-2 ( Fig. 4a,b) . We Fig. 5b ,c and data not shown). So, in line with its effects on overriding the RA-mediated repression of T H 17 differentiation, IL-1β antagonized the effects of IL-2, and this effect was independent of a requirement for co-signaling via IL-23.
The similar effects of IL-1 signaling on the reversal of RA-and IL-2-mediated inhibition of T H 17 differentiation were consistent with our finding that the production of IL-2 by T cells was enhanced about threefold by the addition of RA, at all concentrations tested (Fig. 4c) . This result indicated that the RA-mediated repression of T H 17 differentiation was due at least in part to enhanced IL-2 production. Consistent with the actions of IL-2 in inducing higher expression of the inducible components of IL-2R, the addition of RA also upregulated the expression of IL-2Rα (CD25) and IL-2Rβ (CD122) (Fig. 4d) . Notably, neither the enhanced IL-2 production nor the upregulation of the expression of components of the IL-2 receptor by RA was significantly affected by IL-1β (Fig. 4c,d) , which suggested that the principal effect of IL-1β in blocking the effects of RA was probably due to interference with IL-2 signaling downstream of receptor binding of IL-2. Accordingly, blockade of IL-2 signaling reversed the reciprocal effects of RA on the T H 17 cell-iT reg cell developmental balance, similar to the effects induced by IL-1β (Fig. 4e,f) . Furthermore, in CD4 + T cells deficient in STAT5 expression (and thus IL-2 signaling), the effects of RA in repressing IL-17 expression in favor of Foxp3 expression were similarly overridden and were not further augmented by IL-1β signaling (Fig. 4e,f) . Thus, although RA acted to enhance IL-2 production and expression of the inducible components of the IL-2 receptor by T cells, the reversal of RA-mediated effects by IL-1β signaling appeared to be mediated mainly through interference of IL-2 signaling and not through altered expression of IL-2 or its receptor. 
A r t i c l e s of either RA or RA plus IL-1β. Consistent with its effects on enhancing the expression of IL-2 and its receptor, RA enhanced the tyrosine-phosphorylation of STAT5 in T H 17 cells, a result that was not altered substantially by concurrent IL-1 signaling (Fig. 5a) . In contrast, RA had no effect on IL-6-induced tyrosine-phosphorylation of STAT3, whereas the addition of IL-1 resulted in a substantial increase in tyrosine-phosphorylated STAT3 (Fig. 5a) . The effect of IL-1 signaling on differentiating T H 17 cells resulted in both increased and more-sustained tyrosine-phosphorylation of STAT3 (Fig. 5b) and was not limited to IL-6-induced tyrosine-phosphorylation of STAT3, as we obtained similar results when STAT3 was activated downstream of signaling by IL-21 ( Supplementary Fig. 6 ) or IL-23 ( Fig. 5c) . Therefore, while IL-1 signaling failed to directly repress the RA-mediated enhancement of IL-2-induced tyrosine-phosphorylation of STAT5, it did alter the ratio of tyrosine-phosphorylated STAT5 to tyrosine-phosphorylated STAT3 through its enhancement of IL-6-, IL-21-and IL-23-induced tyrosine-phosphorylation of STAT3, which established an indirect mechanism by which IL-1 might act in concert with each of the STAT3-activating T H 17-pathway cytokines to override RA-mediated, IL-2-dependent repression of T H 17 cell development. Because of its failure to affect RA-mediated effects on the T H 17 cell-iT reg cell balance during early differentiation ( Supplementary  Fig. 5 ), we chose IL-23 to further investigate mechanisms by which IL-1 signaling might alter the abundance of phosphorylated STAT3. We initially assessed the effects of IL-1 upstream of the tyrosinephosphorylation of STAT3. The addition of IL-1 significantly increased and sustained the rapid tyrosine-phosphorylation of Jak2 induced by activation of the IL-23 receptor (Fig. 5d) . The autophosphorylation of Jak2 that is induced by heterodimerization of the IL-23 receptor activates the tyrosine kinase activity of Jak2, which in turn acts to tyrosine-phosphorylate STAT3 that is recruited to the receptor complex. The tyrosine-phosphorylation of Jak2 and STAT3 is competitively inhibited by SOCS3, which is rapidly induced by STAT3 activation in a negative feedback loop 26 . We reasoned, therefore, that IL-1 might modulate the phosphorylation of Jak2 and/or STAT3 through effects on SOCS3 expression. Indeed, while IL-1 signaling alone had no effect on the expression of Socs3 mRNA, it significantly inhibited the expression of Socs3 mRNA induced by IL-23 ( Fig. 5e) , which indicated that IL-1-dependent inhibition of Socs3 expression contributed to the enhanced tyrosine-phosphorylation of STAT3.
NF-κB and mitogen-activated protein kinase signaling cascades are activated downstream of ligation of the IL-1 receptor. We therefore assessed the effects of specific inhibitors of NF-κB and the kinases Jnk2, Erk and p38 on IL-1-induced modulation of the tyrosinephosphorylation of STAT3 and modulation of Socs3 mRNA; we included an inhibitor of Jak2 as a control. Notably, of the inhibitors of IL-1 signaling examined, only the inhibitor of NF-κB blocked the enhancement of tyrosine-phosphorylation of STAT3 induced by IL-23, and this was associated with reversal of the suppression of Socs3 expression (Fig. 5f,g and Supplementary Fig. 7 ). This result suggested that IL-1-induced activation of NF-κB might repress SOCS3 expression as a mechanism for enhancing the abundance of tyrosine-phosphorylated STAT3. Accordingly, T H 17 cells derived from mice with specific deficiency in the NF-κB component RelA in CD4 + T cells (Rela fl/fl Cd4-Cre mice) showed no enhancement in the induction of tyrosine-phosphorylation of STAT3 by co-signaling via IL-1 and IL-23 (Fig. 5h) . That finding was in agreement with a published study of a hepatocyte cell line, in which after a transient, modest early enhancement in the induction of SOCS3 expression, IL-1 repressed IL-6-induced expression of SOCS3 via NF-κB 27 . In addition to its effects on the tyrosine-phosphorylation of STAT3, we found that IL-1 signaling increased the phosphorylation of Ser727 of STAT3 via the p38 kinase pathway (Supplementary Fig. 7a,b) , an effect that has been shown to potentiate the actions of the STAT3 homodimer 28 . However, this effect was more transient than the IL-1-induced tyrosine phosphorylation of STAT3 and was independent of a requirement for co-signaling via IL-23 (or IL-6) ( Supplementary Fig. 7a,b) . This suggested that any effects on the serine-phosphorylation of STAT3 would probably be secondary to the principal effects on tyrosine-phosphorylation modulated by the NF-κB-SOCS3 axis.
Finally, we directly established a role for IL-1-mediated repression of SOCS3 in overriding the RA-mediated inhibition of T H 17 differentiation, as the inhibitory effect of RA was largely mitigated by specific npg deletion of Socs3 in developing T H 17 cells (Fig. 6) . Thus, delivery of Cre recombinase to naive CD4 + T cells from Socs3 fl/fl mice via a TatCre fusion protein led to a reduction in RA-induced Foxp3 expression and enhancement of IL-17 that was similar in the presence of IL-23 or IL-1β (Fig. 6) . Collectively, these data identified a SOCS3-dependent mechanism by which IL-1-induced NF-κB signaling regulated the amplitude and duration of STAT3 tyrosine-phosphorylation induced by T H 17-polarizing cytokines. (Fig. 7a) . The decrease in STAT3 binding caused by the addition of RA was reversed in STAT5-deficient cells (Fig. 7a) , consistent with the actions of RA in enhancing IL-2-dependent signaling via STAT5. The addition of IL-1β reversed both the RA-induced increase in binding of STAT5 and decrease in binding of STAT3 (Fig. 7a) , consistent with the augmented phosphorylation of STAT3 induced by IL-1 signaling (Fig. 5b-f) .
IL-1b modulates STAT3 and STAT5 binding to consensus sequences
At the intergenic enhancer downstream of Il17a noted above, the binding of both STAT3 and STAT5 was unaffected by addition of RA, although both were significantly affected by IL-1β (Fig. 7a) , Competition between phosphorylated STAT5 and STAT3 in binding to the CNS2 intronic enhancer of Foxp3 has been proposed as regulating the heritable maintenance of Foxp3 expression and, thus, the stability of the T reg cell developmental program 29, 30 . We found that RA, by enhancing the binding of STAT5, also restricted the IL-6-mediated binding of STAT3 at CNS2 in the Foxp3 locus during T H 17 differentiation but was outcompeted by increased binding of STAT3 promoted by IL-1 (Fig. 7b) . Consistent with those results, while IL-1 alone had no effect on repressing Foxp3 expression during iT reg cell development (Supplementary Fig. 8a) , it substantially augmented the limited extinction of Foxp3 expression induced by IL-6 in secondary cultures of sorted Foxp3 + T cells derived from Il17f Thy-1.1 Foxp3 GFP dual-reporter mice (Supplementary Fig. 8b) . Indeed, even in the presence of exogenous RA, which promoted stability of Foxp3 expression, greater than 50% of cells extinguished their expression of Foxp3, with a significant population converting into IL-17F-producing cells (Supplementary Fig. 8b) . Thus, IL-1 acted cooperatively with IL-6 to subvert the Foxp3-iT reg cell program in favor of T H 17 cell development due at least in part to its actions in altering the relative binding of phosphorylated STAT3 and STAT5 at the CNS2 enhancer element in the Foxp3 locus.
DISCUSSION
The early developmental programs of iT reg cells and T H 17 cells are intimately linked, reflected in the coexpression of the lineagespecifying transcription factors Foxp3 and RORγt downstream of TGF-β signaling 5, 6 . The balance between the antagonistic effects of RA and IL-2, which promote iT reg cell development while suppressing T H 17 cell development, and those of IL-6 and IL-1, which promote T H 17 cell development while suppressing iT reg cell development, is particularly critical in determining homeostatic immunity versus host-protective immunity to microbes in the intestines, where production of RA by resident DCs normally favors antimicrobial tolerance. Here we found that IL-1 signaling overrode the effects of 
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A r t i c l e s the RA-IL-2 axis in promoting iT reg cell differentiation to allow a hostprotective T H 17 response to an enteric pathogen, and we defined a mechanism by which IL-1 signaling modulated the T H 17 cell-iT reg cell developmental balance. By enhancing the amplitude and duration of phosphorylated STAT3 activity induced by T H 17-specifying cytokines (for example, IL-6 and IL-23), IL-1 altered the ratio of phosphorylated STAT3 to phosphorylated STAT5 in developing T cells to enhance T H 17 cell development at the expense of iT reg cell development. Indeed, by favoring the binding of phosphorylated STAT3 over that of phosphorylated STAT5 at the CNS2 intronic enhancer in the Foxp3 locus, IL-1-dependent potentiation of STAT3 signaling directly subverted the T reg cell-stabilizing function of IL-2 promoted by RA, thereby contributing to plasticity in the T reg cell developmental program 14, 15, 31, 32 . These findings extend the role of proinflammatory cytokines in overriding a dominant program of T reg cell development in the intestines to enable the recruitment of T H 17 cell-mediated host defense and provide a mechanism by which IL-1 acts together with T H 17 cell-specifying cytokines to promote T H 17 cell development.
Although the contribution of IL-1 to T H 17 differentiation is well established 2, 16 , the mechanism of its action has been unclear. Here we identified a link between IL-1 signaling and repression of SOCS3 expression as a mechanism for specifically augmenting signaling by STAT3 but not that of STAT5. Published studies have detailed the structural basis by which SOCS3 interacts with the complex composed of the signal-transducing receptor gp130 and kinase Jak1 following ligand-mediated trans-phosphorylation of the cytoplasmic domain of receptors of the IL-6 family, which explains the specificity of SOCS3 for this family of receptors 33, 34 , and presumably non-gp130 receptors such as the structurally related IL-23R 26 , but not the IL-2 receptor. The rapid induction of SOCS3 expression downstream of signaling via IL-6 (or IL-23) provides a negative feedback loop that rapidly terminates signaling via the IL-6 receptor or IL-23 receptor by inhibiting receptor-bound Jak1 or Jak2, respectively. Through repression of SOCS3 expression, IL-1 indirectly sustains Jak-STAT interactions that potentiate phosphorylated STAT3 actions. Absent comparable effects on IL-2 receptor-induced phosphorylation of STAT5, IL-1 signaling effectively shifts the ratio of phosphorylated STAT3 to phosphorylated STAT5 in favor of phosphorylated STAT3, providing a competitive advantage for the binding of phosphorylated STAT3 to shared DNA target sequences, as demonstrated in our chromatin-immunoprecipitation studies.
Interestingly, IL-1 augmented the IL-21-induced phosphorylation of STAT3 similarly to that induced by IL-6 and IL-23. Although the IL-21 receptor is unlike other common γ-chain cytokine receptors in activating mainly STAT3, not STAT5, as far as we are aware, a direct role for SOCS3 in modulating signaling via the IL-21 receptor has not been defined. Additional studies will be needed to determine whether the IL-21 receptor is unusual among common γ-chain cytokine receptors in recruiting SOCS3 or whether other effects of IL-1 signaling contribute to the increased phosphorylation of STAT3 induced by IL-21. It is notable that TGF-β has been reported to contribute to T H 17 cell development through the inhibition of IL-6-and IL-21-induced SOCS3 expression 35 , although another study has found that TGF-β also increases STAT5 phosphorylation 36 , an effect we did not observe here for IL-1 signaling. Thus, although both IL-1 and TGF-β might repress SOCS3 expression in concert with T H 17-polarizing cytokines, albeit via fundamentally different signaling pathways, IL-1 would seem to 'preferentially' alter the ratio of phosphorylated STAT3 to phosphorylated STAT5 in favor of phosphorylated STAT3. In this context, it is of interest that T H 17 cell development can occur in the absence of TGF-β signaling, contingent on co-signaling by IL-1β with either IL-6 or IL- 23 (ref. 37) . It would therefore be of interest to determine whether this effect is mediated by IL-1-induced inhibition of SOCS3.
In addition to positioning SOCS3 for inhibition of the Jak catalytic domain, docking of the SH2 domain of SOCS3 onto phosphorylated Tyr759 of the IL-6-activated gp130 cytoplasmic domain inhibits binding of the cytosolic tyrosine kinase SHP2, which activates signaling via mitogen-activated protein kinases and phosphatidylinositol-3-OH kinase induced by IL-6 and, presumably, IL-23. Thus, while it potentiates the phosphorylation of STAT3, IL-1-mediated repression of SOCS3 might also potentiate STAT3-independent signals from the IL-6 receptor, the effects of which have not been explored. Moreover, deficiency in SOCS3 has been shown to increase activation of STAT1 in myeloid cells 38 , which raises the possibility that IL-1-induced suppression of SOCS3 might also affect the T H 17 cell-iT reg cell developmental balance via modulation of STAT1. It would be of interest to examine these issues in future studies.
A published report has found that IL-1 signaling increases expression of the transcription factors IRF4 and RORγt, both of which are required for T H 17 differentiation 16 . Expression of IRF4, which, unlike RORγt 39 , is central to the development of other effector cells in addition to T H 17 cells, appears to be regulated mainly by TCR signals and is STAT independent. Hence, increased expression of IRF transcription factors is probably not mediated by the STAT3-amplifying effects of IL-1 signaling we have described here. However, through cooperative binding with the transcription factor BATF at consensus motifs in multiple genes associated with the T H 17 lineage 40, 41 , IRF4 contributes to chromatin accessibility at many sites that are also targeted by STAT3 (ref. 42) , as well as sites targeted by both STAT3 and STAT5 (ref. 15) . Thus, in addition to any STAT-independent effects that IL-1 signaling might have on enhancing IRF4 expression, it can also indirectly modulate the effects of IRF4 actions by altering the balance of STAT binding at composite consensus sites in target genes. In contrast to IRF4 expression, RORγt expression is STAT3 dependent 43 . Thus, the effects of IL-1 on augmenting the amplitude and duration of the tyrosine-phosphorylation of STAT3 probably contribute to enhanced expression of RORγt during T H 17 differentiation, whether early, downstream of IL-6 signaling, or later, following expression of the IL-23 receptor.
iT reg cells differ from thymic T reg cells in their tendency to lose Foxp3 expression during successive rounds of cell division. This reflects differences in the methylation status of CpG islands within CNS2 of the Foxp3 locus 30, 44, 45 . CNS2 is highly methylated in newly generated iT reg cells, whereas thymic T reg cells and mature iT reg cells have undergone demethylation of CNS2, which enables binding of Foxp3 and Runx1, among other factors, that confers stable expression of Foxp3 under limiting IL-2 conditions 32 . Although the mechanism by which CNS2 becomes demethylated during T reg cell maturation remains to be fully elucidated, it has been found that CNS2 is the main site of IL-2-induced binding of STAT5 in the Foxp3 locus 32 , and, in contrast to other factors that bind CNS2, STAT5 can bind CNS2 regardless of its methylation status 36 . Although it remains unproven, this suggests that STAT5 might be an important factor in recruiting demethylation complexes to CNS2, in addition to its function in sustaining the competency of CNS2 in immature iT reg cells as they divide 32 . The data presented here would favor a model wherein IL-1 signaling in intestinal T cells responding to enteropathogenic infection is important for overriding the RA-IL-2-STAT5 axis in favor of enhanced, sustained STAT3 signaling that inhibits binding of STAT5 to Foxp3 CNS2. This would silence expression of Foxp3 npg while promoting expression of the gene encoding RORγt and other genes associated with the T H 17 lineage that contain consensus sequences regulated by competitive antagonism of STAT5 binding versus STAT3 binding and thereby deviate nascent or immature iT reg cells toward T H 17 cell development. These findings extend the role of proinflammatory cytokines in overriding a dominant program of T reg cell development in the intestines to enable the recruitment of T H 17 cell-mediated host defense and provide a rationale for the consideration of IL-1 blockade to reestablish homeostasis in the treatment of chronic inflammatory diseases mediated by the T H 17 pathway.
METHODS
Methods and any associated references are available in the online version of the paper. .Cg-Tg(Cd4-Cre) 1Cwi (Cd4-Cre) mice were from Taconic, and B6.CD45.1 mice were from Frederick Cancer Center. All strains were on a C57BL/6 (B6) background. All intercrosses to generate additional strains, such as wild-type and IL-1R-deficient dual reporter (Il17f Thy-1.1 Foxp3 GFP ) mice, Il17f Thy-1.1 CD45.1 + CD45.2 + mice and Stat5b fl/fl Cd4-Cre mice, were generated by crosses in UAB's breeding facility. Animals were bred and maintained under specific pathogen-free condition in accordance with institutional animal care and use committee regulations.
C. rodentium infection and mAb treatments. C. rodentium strain DBS100 (American Type Culture Collection) was used for all inoculations, with the exception of experiments in which whole-body imaging was performed. For imaging experiments, the bioluminescent C. rodentium strain ICC180 (derived from DBS100) was used 46 . This strain has a constitutive luxCDABE operon that encodes luciferase of the nematode Photorhabdus luminescens. C. rodentium strain DBS100 was grown at 37 °C in LB broth, and C. rodentium strain ICC180 was grown in LB broth containing kanamycin (100 µg/ml). Mice were inoculated with 2 × 10 9 colony-forming units of C. rodentium (a high dose) in a total volume of 200 ml of PBS via gastric gavage.
For depletion of Il17f Thy-1.1 cells in vivo, mice were given intraperitoneal injection of 400 µg anti-Thy-1.1 (19E1.2; University of Alabama-Birmingham Epitope Recognition and Immunoreagent Core Facility) on days 3 and 7 after infection. In all studies, age-and sex-matched mice 6-12 weeks of age were used.
Bioluminescence imaging. Mice were anesthetized with isoflurane and were placed in the supine position in a custom-built chamber for imaging with the IVIS-100 system and Living Image Software (Xenogen). Baseline images were obtained before gavage with 2 × 10 9 colony-forming units of C. rodentium strain ICC180, and whole-body images were obtained at a binning of 4 over 1 for 3 min at the appropriate times after infection with C. rodentium ICC180. Luminescence emitted from the same gate in individual mice was quantified as counts per second, and pseudocolor images represent light intensity generated as a measure of colonization of the luminescent bacterial strain.
Cell isolation, in vitro T cell differentiation, protein transduction and inhibitor treatment. Naive CD4 + T cells from spleens or lymph nodes of 8-to 10-week-old mice were purified by sorting on a FACSAria II (BD Bioscience) with gating on the CD4 + CD25 − CD62L hi CD44 lo fraction. Isolated CD4 + T cells were cultured in R-10 medium (RPMI medium containing 10% FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate, nonessential amino acids, 50 µM β-mercaptoethanol and 2 mM l-glutamine). For stimulation with plate-bound polyclonal antibodies, sorted CD4 + T cells were stimulated with 5 µg of plate-bound anti-CD3 (145-2C11; BD Pharmingen) and 1 µg/ml of soluble anti-CD28 (37.51; BD Pharmingen). For polyclonal feeder-based stimulation, sorted CD4 + T cells were stimulated with 1 µg/ml of soluble anti-CD3 (identified above) in presence of in presence of populations of feeder cells obtained from the spleen or MLNs of Il1b −/− mice, then irradiated and depleted of T cells. For antigen-specific stimulation, sorted naive OT-II CD4 + T cells (which have transgenic expression of an ovalbuminspecific TCR) were activated with 5 µg/ml ovalbumin peptide in presence of populations of splenic feeder cells obtained from Il1b −/− mice, then irradiated and depleted of T cells. In all cases in which feeder cells were used for T H 17 polarization, T cells and feeder cells were added at a ratio of 1:1. All cultures were done in a volume of 200 µl in 96-well U-bottomed plates. For T H 17 or iT reg polarization, the following exogenous cytokines or antibodies were added (concentrations in parentheses), unless stated otherwise: IL-6 (20 ng/ml; R&D Systems); TGF-β (2 ng/ml; R&D Systems); IL-21 (10 ng/ml; R&D Systems); IL-23 (5 ng/ml; R&D Systems); IL-1β (20 ng/ml; R&D Systems), human IL-2 (1-100 U; Roche), anti-IL-4 (10 µg/ml; XMG1.2; prepared in-house); anti-IFN-γ (10 µg/ml; 11B11; prepared in-house); and anti-IL-2 (10 µg/ml; JES6-1A12; eBioscience). All-trans RA (Sigma) was added at various concentrations (1-100 nM), and the RA antagonist LE540 (Wako) was added at a concentration of 1 µM.
For the purification of Foxp3 + CD4 + T cells, Foxp3-GFP + cells were sorted by flow cytometry and subjected to various conditions. For the purification of CD4 + single-positive thymocytes, CD8 + T cells were initially removed by depletion via magnetic-activated cell sorting (Mouse CD8α MicroBeads; Miltenyi Biotec), and CD4 + single-positive cells were further purified by isolation of the flow-through by magnetic-activated cell sorting (Mouse CD4 + T Cell Isolation Kit II; Miltenyi Biotec).
In experiments in which cells were treated with cell-signaling inhibitors, recovered cells were washed and then were deprived of serum in complete medium for 1 h before addition of the following reagents (concentrations in parentheses): the Jak2 inhibitor AG490 (50 µM), the Jnk inhibitor SP600125 (1 µM), and the NF-κB inhibitor PDTC (1 µM). With the exception of PDTC (Sigma), all inhibitors were from Calbiochem.
In experiments in which naive CD4 + T cells were transduced by TAT-Cre protein, sorted naive CD4 + T cells from Rosa26 TdTomato fl/+ reporter mice with a loxP-flanked STOP cassette were initially standardized by transduction of TAT-Cre. Cells were incubated for 15-20 min at 37 °C in 1 ml of 100 µg/ml TAT-Cre peptide in serum-free RPMI medium, then were washed and suspended in RPMI medium containing IL-7 (10 ng/ml) plus 10% FCS, followed by incubation for 6, 12, 24 or 48 h; maximum expression of the reporter was observed at 24 h. Subsequently, sorted naive CD4 + T cells from Ai14 td-Tomato reporter and Socs3 fl/fl mice were treated in tandem with TAT-Cre or control peptide and were cultured for 24 h in IL-7-containing medium, followed by polarization under T H 17 conditions, with the additional culture modifications indicated in figure legends.
Flow cytometry, including flow cytometry with phosphorylationspecific antibodies. The following mAbs were used for sorting cells by flow cytometry: anti CD4-eFlour 780 (eBioscience, clone RM4-5); anti-CD25-FITC (BD Pharmingen, clone 7D4); anti-CD62L-PE (eBioscience, clone MEL-14); and anti-CD44-APC (eBioscience, clone IM-7). For flow cytometry and intracellular staining, the following mAbs were used: fluorescein isothiocyanateor peridinin chlorophyll protein-cyanine 5.5-conjugated anti-CD3 (145-2C11; eBioscience); phycoerythrin-indotricarbocyanine-conjugated anti-CD4 (RM4-5; eBioscience); allophycocyanin-conjugated anti-IL-17A (17B7; eBioscience); peridinin chlorophyll protein-cyanine 5.5-conjugated anti-CD25 (PC61.5; eBioscience), peridinin chlorophyll protein-cyanine 5.5-conjugated anti-CD45.1 (A20; eBioscience) and phycoerythrin-conjugated anti-RORγt (AFKJS-9; eBioscience). Differentiated T H 17 cells were directly stained with anti-Thy-1.1 (OX-7; BD Pharmingen) without secondary stimulation. Only in cases in which intracellular IL-17A was detected, cells were stimulated for 4 h with PMA (phorbol 12-myristate 13-acetate; 50 ng/ml; Sigma) and ionomycin (750 ng/ml; Calbiochem) in the presence of Golgi Plug (BD Pharmingen). For detection of intracellular IL-17A and Foxp3, cells were resuspended in Foxp3 staining Buffer (eBioscience). In all cases, LIVE/DEAD Fixable Near-IR Dead Cell Stain (Invitrogen) was included before surface staining to exclude dead cells in flow cytometry.
For flow cytometry with phosphorylation-specific antibodies, sorted naive CD4 + T cells were differentiated with plate-bound anti-CD3 and soluble anti-CD28 (both identified above) under T H 17-polarizing conditions alone or in presence of RA or RA plus IL-1β. After 4 d, cells were allowed to 'rest' briefly in medium at a neutral pH before being stimulated for 20 min with IL-6 alone (50 ng/ml; R&D Systems) or with IL-2 (500 U/ml). The cells were then washed and suspended in prewarmed PBS before being fixed for 10 min, in an incubator at 37 °C, with 4% paraformaldehyde. The cells were washed again and resuspended in ice-cold phospho-wash buffer (PBS containing 1× HALT protease inhibitor (78437; Thermo Scientific)) before the addition of chilled 100% methanol in drops and incubation for 30 min, followed by two washes in PBS containing 0.05% Tween. Cells were preincubated for 15 min in PBS-Tween containing 3% goat serum and 1 µl Fc block before incubation for 1 h with phycoerythrin-conjugated antibody to STAT3 phosphorylated at Tyr705 (612569; BD Biosciences) or Alexa Fluor 647-conjugated npg
